ArticleHealth security
Public funding of clinical-stage antibiotic development in the United States and European Union.
Article in Health security. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- An evaluation of the US public-private Combating Antibiotic-Resistant Bacteria Accelerator (CARB-X) initiative.Health affairs scholar · 2026Article
- 'Piloting a framework for analysing the public contributions to R&D: new antibiotics in focus'.Journal of pharmaceutical policy and practice · 2025Article
- Synthesis and Characterization of Dendronized Gold Nanoparticles Bearing Charged Peripheral Groups with Antimicrobial Potential.Nanomaterials (Basel, Switzerland) · 2022Article
- Article
- Antibiotics-From There to Where?: How the antibiotic miracle is threatened by resistance and a broken market and what we can do about it.Pathogens & immunity · 2018Review
- Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps.The Journal of antibiotics · 2017Review
- Lipophilic teicoplanin pseudoaglycon derivatives are active against vancomycin- and teicoplanin-resistant enterococci.The Journal of antibiotics · 2017Article
- The ABCs of the US Broad Spectrum Antimicrobials Program: Antibiotics, Biosecurity, and Congress.Health securityArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The health and national security challenge of antibiotic resistance has led governments to adopt policies to stimulate new antibiotic R&D. Government programs that directly fund late-stage clinical development of antibiotics have emerged, including the Broad Spectrum Antimicrobial Program of the Biomedical Advanced Research and Development Authority in the United States, and the New Drugs for Bad Bugs program of the Innovative Medicines Initiative in the European Union. These efforts are collectively investing nearly $1 billion and are supporting nearly 20% of the global antibiotic pipeline. This article describes these programs, including the antibiotics and their targeted pathogens and clinical indications, as well as program mechanisms for project eligibility, selection, governance, funding, and IP management. Preliminary assessment of the impact of these mechanisms on the success of the programs is provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.